Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Monalizumab, an antibody targeting NKG2A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Oleclumab, an antibody targeting CD73.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ianalumab, an antibody targeting BAFF-R.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Cetrelimab, an antibody targeting PD-1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bemarituzumab, an antibody targeting FGFR2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Nadunolimab, an antibody targeting IL1RAP.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Magrolimab, an antibody targeting CD47.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Garetosmab, an antibody targeting Activin A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Cobolimab, an antibody targeting TIM-3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Cendakimab, an antibody targeting IL-13.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Apamistamab, an antibody targeting PTPRC.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Abelacimab, an antibody targeting Factor XI.